Just a quick note to you folks,

Thanks for the clarification note you folks left on the page for the latest Hooked podcast (#16).

-Scott

To the folks who have followed this thread,

There is a rather significant update relative to the knowledge of these drugs: melanotan-1 (afamelanotide / Scenesse) has received approval from the Italian Medicines Agency for therapeutic treatment of the photosensitivity aspect of the orphan disease erythropoietic protoporphyria. This decision made on May 5, 2010 took immediate effect allowing doctors to prescribe and administer the pharmaceutical there. As well the Italian law which permitted this approval ensured that the drug was reimbursable through the Italian National Health System.

More info: http://melanotan.org/#Scenesse

This approval is likely the first domino in a line of approvals for this drug in treatment of a small series of light-affected dermal orphan indications.

Thanks,

-Scott Stevenson
Melanotan.org - afamelanotide Founder & Admin